Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

With predictions showing that 131.5 million people worldwide will be living with dementia by
2050, an understanding of the molecular mechanisms underpinning disease is crucial in the …

In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …

Tau aggregation into insoluble filaments is the defining pathological hallmark of tauopathies.
However, it is not known what controls the formation and templated seeding of strain-specific …

Hyperphosphorylation of the neuronal tau protein is a hallmark of neurodegenerative
tauopathies such as Alzheimer's disease. A central unanswered question is why tau …

Introduction Phosphorylated tau (p‐tau) in cerebrospinal fluid (CSF) is an established
Alzheimer's disease (AD) biomarker. Novel immunoassays targeting N‐terminal and mid …

Tauopathies are characterized by cerebral accumulation of Tau protein aggregates that
appear to spread throughout the brain via a cell-to-cell transmission process that includes …

Lewy bodies (LBs) are complex, intracellular inclusions that are common pathological
features of many neurodegenerative diseases. They consist largely of aggregated forms of …

Microglia are the cells that comprise the innate immune system in the brain. First described
more than a century ago, these cells were initially assigned a secondary role in the central …

Accumulation and spread of tau in Alzheimer's disease and other tauopathies occur in a
prion-like manner. However, the mechanisms and downstream consequences of tau …